Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine plus atazanavir/ritonavir or simplify to abacavir/lamivudine plus atazanavir
Kevin Robertson, Paul Maruff, Lisa L Ross, David Wohl, Catherine B Small, Howard Edelstein, Mark S Shaefer
Journal of NeuroVirology | SPRINGER | Published : 2019
The study was funded by ViiV Healthcare. The sponsor developed the study design with input from prospective investigators.